Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiforme

Key Points

• The research aims to investigate a novel treatment approach for glioblastoma multiforme using surface-engineered nanoparticles.
• Developed dual drug-loaded liposomal nanoparticles (TTL) for tumor targeting.
• Assessed the ability of TTL to cross the blood-brain barrier.
• Combined TTL with radiation therapy in animal models of glioblastoma; analyzed tumor responses and survival rates.
• Conducted gene expression analysis to identify differentially expressed genes related to DNA damage and cell death.
• Investigated the inhibition of mTOR/MAPK pathways by the TTL and radiation combination.
• TTL effectively crossed the blood-brain barrier and targeted tumors.
• Combined treatment with TTL and radiation significantly improved tumor suppression and survival in glioblastoma models.
• Gene expression analysis revealed key genes linked to DNA damage and cellular death pathways.
• TTL-EV plus radiation inhibited critical cancer pathways (mTOR/MAPK), enhancing tumor sensitivity to treatment.